BPM31510
BPM31510 (ubidecarenone) is BERG’s leading product candidate. BPM31510 works by correcting cancer cell metabolism, thereby reactivating apoptosis.
BPM31510 is currently progressing through clinical trials for the treatment of a number of solid tumors. Early phase trials have appeared to demonstrate anti-tumor activity with an acceptable safety profile.
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to BPM31350 for the treatment of pancreatic cancer and epidermolysis bullosa in January 2018 and May 2018, respectively.
BPM31510 is also being tested in a type of brain tumor called glioblastoma multiforme, a type of skin cancer called squamous cell carcinoma, a number of other solid tumors and a skin disorder called epidermolysis bullosa.
BPM31510 in clinical development
Solid Tumors | Monotherapy and Combination therapy | Intravenous
- Discovery Complete
- Preclinical Complete
- Phase 1 Complete
- Phase 2
- Phase 3
Pancreatic Tumors | Monotherapy and Combination therapy | Intravenous
- Discovery Complete
- Preclinical Complete
- Phase 1 Complete
- Phase 2 Complete
- Phase 3
Glioblastoma Multiforma | Monotherapy | Intravenous
- Discovery Complete
- Preclinical Complete
- Phase 1 Complete
- Phase 2
- Phase 3
Squamous Cell Carcinoma | Monotherapy | Topical – cream
- Discovery Complete
- Preclinical Complete
- Phase 1 Complete
- Phase 2 Complete
- Phase 3
Epidermolysis Bullosa | Monotherapy | Topical – cream
- Discovery Complete
- Preclinical Complete
- Phase 1 Complete
- Phase 2
- Phase 3